To assess patient reported variables as predictors of change in disease activity and disability in early rheumatoid arthritis (RA).
In patients recruited up to 2002 DAS28 reduced more quickly in those with greater pain at baseline (by 0.01 units/month of DAS28 per centimetre pain VAS; p=0.024); in patients recruited after 2002 the effect for pain was stronger (by 0.01 units/month; p=0.087). DAS28 reduction was greater with longer EMS.
In both cohorts fall in HAQ-DI (p=0.006) was greater in patients with longer EMS duration, but pain and fatigue were not significant predictors of change in HAQ-DI.
Conclusion
Patient reported fatigue, pain and stiffness at baseline are of limited value for the prediction of RA change in disease activity (DAS28) and activity limitation (HAQ-DI). 1, 2 . Measurement of these subjective indicators of health status can aid clinical assessment 3 and there is evidence that they can be useful to help predict RA remission. For example, a study involving 103 RA patients from Japan found an inverse association between remission and greater pain and fatigue at baseline after a 7 year follow-up 4 .
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Similarly, greater baseline pain was associated with reduced odds of remission at 6 and /or 12 months in the French early inflammatory arthritis 'ESPOIR' cohort 5 . Thus, patient reported measures may be rapid and cost-effective tools for the prediction of outcome in RA. However, before these variables can be useful in a clinical setting, further evidence to support their application is needed. The present study evaluated patient reported measures (fatigue, pain and early morning stiffness) alongside traditional predictors of outcome to investigate their value in predicting the rate of change in disease activity and disability an early RA cohort.
METHODS

Subjects
Yorkshire Early Arthritis Register (YEAR) is an observational inception cohort whose subjects were aged over 18 and IgM rheumatoid factor (RF) at baseline. RF was measured using standard nephelometric assays and anti-citrullinated peptide antibodies (ACPA) were determined retrospectively on stored samples, using previously described methods 8 .
Data analysis
Baseline demographic and disease characteristics were summarized in terms of means and standard errors (continuous variables) and percentages (categorical variables). Multilevel models (random intercepts, fixed slopes) were constructed to evaluate baseline predictors of DAS28 and HAQ-DI measured at baseline, 6 and 12 months. These were 2-level models in which repeated measurements over time (level 1) were nested within patients (level 2). These models included an indicator for 'cohort' (before or after 2002, when the treatment protocol changed), and a variable indicating month, which was treated as a continuous covariate. Interactions were added between each predictor and cohort, to show whether associations with baseline DAS28 or HAQ-DI differed by cohort, and between each predictor and month, to show whether the predictor was associated with change in DAS28 over time.
Additionally, 3-way interaction terms between each predictor, month and cohort were added to explore whether changes over time differed by cohort. The interaction terms were sequentially discarded in order of least significance until only significant terms (where p ≤ 0.1) remained in the model; 2-way interactions were retained irrespective of significance if both variables were included in a significant 3-way interaction. Linear change was assumed over time. Pseudoadjusted-R-squared was calculated as the adjusted-R-squared between observed and predicted values of each outcome. R-squared estimates obtained in each imputed dataset were averaged after using Fisher's r to z transformation. We considered whether random slopes were more suitable than fixed slopes. Formally testing for random slopes using the standard likelihood ratio approach is not currently supported for multiply-imputed datasets in our chosen analysis package. We compared the coefficients between models that included fixed or random slopes for time and found them to be very similar, and the conclusions regarding which main effects and interactions were statistically significant remained unaffected, therefore we opted to retain the simpler model.
Continuous rather than dichotomous outcomes (e.g. remission or nonremission, HAQ above or below a threshold value) were used in order to retain statistical power. To this end, as HAQ-DI represents an ordinal scale 9 , this variable was transformed using Rasch analysis so that it could be analysed as an interval-scaled variable 10 . As well as traditionally reported predictors of RA outcome -including gender, antibody status and age -patient reported pain, fatigue and duration of early morning stiffness were also included as predictors in the models. Continuous variables were centred at the mean prior to analysis.
EMS was not normally distributed and was therefore divided into 5 approximately equal-sized groups: <30, 30-59, 60-119, 120-179, and ≥180
minutes. Correlation between RF and ACPA status was 0.56 and considered low enough for both variables to be included in the models simultaneously.
Missing Data
Missing data were accounted for using multiple imputation (MI) by chained equations and 50 imputed datasets, the results from which were combined according to Rubin's rules 11 . Predictive mean matching with 10 nearest neighbours was used to impute continuous variables; for RF and ACPA logistic regression was used. Fifty imputations were chosen for this analysis in order to achieve ≥95% relative efficiency of the MI estimates [11] [12] [13] 
RESULTS
Baseline characteristics and missing data
Numbers of cases recruited to YEAR and included in the final analysis are shown in Figure 1 . From a total of 1415 cases, 690 were recruited between 1997 and 2002 and 725 were recruited after 2002. Baseline characteristics and rates of missingness for variables included in the analysis are given in Table 1 .
YEAR 2b ). In the earlier cohort baseline EMS was not associated with rate of change in DAS28, but in the later cohort, longer duration of EMS was associated with greater reduction in DAS28 (Figures 2c & 2d) . Repeating the final model using only cases with complete data yielded similar results to those obtained through MI, although with lower power. The effect of symptom duration on change over time was reduced in the MI analysis compared to complete cases, whereas the interaction between baseline pain, cohort and change over time was more apparent in the MI analysis.
Change in HAQ-DI Table 3 shows the results of the multilevel model of HAQ-DI. As shown in Pseudo-adjusted-R-squared for the HAQ model was 0.24 (95% CI 0.22, 0.26).
DISCUSSION
This study examined predictors of change in DAS28 and HAQ-DI in early RA, including patient reported measures, pain, fatigue and EMS, alongside traditional predictors of prognosis: gender, age and antibody status. The rate of reduction in DAS28 was greater with increased age at baseline and slower in females than males. It was also faster in those with greater pain or EMS at baseline, especially for our patients recruited after 2002. However, effects attributable to statistically significant variables were small. The measurement error of DAS is 0.6, and therefore a reduction from baseline of twice this (>1.20)
is considered a good response 14 . In comparison, the present analyses These findings are consistent with previously reported associations of patient reported symptoms and other outcomes. Recent data from the ESPOIR cohort found only a moderate correlation of fatigue and pain VAS with simultaneous DAS28 measurement, amongst other patient reported outcomes 15 . Female gender is frequently identified as an independent predictor of adverse outcome in RA, including non-remission 16 and lesser reduction in DAS28 17 and the results from the present study were consistent with this. Although some studies that have found an association between increasing age at baseline and nonremission, this effect is not consistent between studies 16 and therefore, our findings of only slightly faster reduction in DAS28 with increasing age at baseline was not surprising. There have also been several reported associations of increased age at RA onset with less favourable HAQ-DI [18] [19] [20] , and although we did not find an association between rate of change in HAQ-DI and age, baseline HAQ-DI was higher for older patients.
Whether the findings of this study can be applied in the context of modern RA management is influenced by contemporary treatment approaches. Current treat-to-target recommendations for RA management were published in 2010 21 , which was after recruitment to YEAR ended. However, our findings may still be applicable for certain patients, for example those who cannot take full doses of MTX or other DMARDs due to comorbidities or intolerance. The effect of treatto-target on change in DAS28 and HAQ is an area of further study for the authors of this paper.
We are not aware of any other studies that have explored the use of patient reported outcomes to predict change in DAS28 and HAQ-DI in RA. However, several studies have highlighted the contribution of non-inflammatory pain to overall disease activity scores. The pain index of DAS28 (DAS28-P), described by researchers from the Early Rheumatoid Arthritis Network (ERAN) 22 , is the proportion of overall DAS28 derived from its subjective components. Improvement in pain measured using the Short Form 36 questionnaire after 1
year was less likely in patients with higher baseline DAS28-P 22 . Recently, in patients from a Danish cohort of RA patients completing the painDETECT questionnaire (which is designed to classify pain into low, medium or high likelihood of being non-nociceptive), those whose scores indicated nonnociceptive pain had greater overall DAS28 and DAS28-P, measured at the time of questionnaire completion 23 . Therefore, any association of baseline pain with subsequent change in DAS28 (as seen predominantly in our post-2002 cohort) may reflect an association with the subjective DAS28 components, rather than inflammation alone.
EMS is a disabling symptom that fluctuates with RA disease activity 24 , and helps to differentiate patients with RA from non-inflammatory arthralgia 25 . In a prospective study that examined the effect of severity of EMS on early retirement, greater EMS at baseline was correlated with simultaneous measurements of DAS28, pain, and function, and those with severe stiffness at baseline were more likely to retire from employment within 3 years of follow up 26 . Further findings from this study included an absence of association between EMS and radiographic progression, which was later supported by evidence from the Leiden Early Arthritis Clinic and ESPOIR cohorts in which prolonged EMS (>60 minutes) was not associated with poor prognosis in terms of radiographic outcome after 3-7 years, or failure to achieve remission after 5-10 years' follow up 27 . Although our study reported an association of greater EMS at baseline with greater rate of reduction in DAS28 in some patients in conflict with previous reports, the size of the effect was small (up to 0.06 units fall in DAS28 per month) and is unlikely to be clinically significant.
Data on fatigue and pain were captured in the form of VAS. Other methods of assessment are available to measure these variables, but the VAS was chosen because it was simple and quick for patients to complete alongside the other questionnaires that formed part of the study. A systematic review of scales to measure fatigue in RA identified 23 different scales, of which 6, including the VAS, had reasonable evidence of validation 28 . This review found evidence that a VAS performs reasonably well in terms of construct validity and discrimination, but there was little evidence to demonstrate reliability and a lack of a standardised format. However, although the VAS has its limitations, no other measures are superior in terms of validation, and furthermore, the single item VAS likely performs as well as other, more detailed measures of fatigue 29 .
Therefore, we feel the use of VAS was justified.
A significant limitation of this study was the quantity of missing data: 40% and 43% cases had missing values for the 6 and 12 month analyses, respectively. 36, 37 . The quantity of missing data was large for ACPA (39% of cases), so this is a potential source of bias.
An additional strength is the use of DAS28 and HAQ-DI as continuous, rather than categorical or dichotomous (remission/ non-remission) outcomes, thus improving statistical power. Although this study considered three separate patient reported measures as predictors of outcome, it was not possible to assess the prediction value of several other similar variables. These include the RAPID3 38 and SF36 39 , which were not collected in YEAR, and the VAS of global health status, which was collected in YEAR, but was not included in the statistical models because it was strongly correlated with pain VAS. The present study was also limited to examining the predictive value of patient reported outcomes collected at the baseline visit. It is possible that trends in the change of these variables would be more useful as predictors of outcome and therefore could be an area of interest for future study.
In summary, this study showed that patient reported outcomes at baseline, such as pain, fatigue and stiffness are not useful for the prediction of rate of change in disease activity and disability. 
